Kaku K, Araki E, Tanizawa Y, et al. - Researchers conducted this 52-week, open-label, multicentre, treat-to-target trial to test the safety and effectiveness of insulin degludec/liraglutide (IDegLira) compared with its individual components in Japanese patients with type 2 diabetes (T2D) uncontrolled on an oral antidiabetic drug (OAD). This trial randomised 819 individuals 1:1:1 to IDegLira, liraglutide 1.8 mg or degludec, as add-on to pre-trial OAD. In total, gastrointestinal adverse events were encountered by 34.9%, 22.9% and 41.8% of individuals treated with IDegLira-, degludec- and liraglutide. In Japanese patients with T2D, IDegLira was superior to degludec and liraglutide in terms of reduction of HbA1c and superior to degludec in terms of changes in body weight and hypoglycaemia rates.